Observed Response to Ponatinib Among Patients With Resistant and Intolerant Chronic-phase CML With Substantial Prior Second-generation Treatment

Pharmacy Times^® interviewed Hagop Kantarjian, MD, the professor and chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, on one of his presentations at the 62nd ASH Annual Meeting and Exposition. The presentation looks at the efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia (CML) who failed one or more second-generation tyrosine kinase inhibitors.

In this video, Kantarjian explains what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.